Medlive Technology Insider Lowered Holding By 58% During Last Year
Medlive Technology Insider Lowered Holding By 58% During Last Year
Viewing insider transactions for Medlive Technology Co., Ltd.'s (HKG:2192 ) over the last year, we see that insiders were net sellers. This means that a larger number of shares were sold by insiders in relation to shares purchased.
查看內部交易梅德利夫科技有限公司的S(HKG:2192)過去一年,我們看到內部人士是淨賣家。這意味著,與購買的股票相比,內部人士出售的股票數量更多。
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
儘管就長期投資而言,內幕交易並不是最重要的事情,但我們會認為完全忽視內幕交易是愚蠢的。
View our latest analysis for Medlive Technology
查看我們對Medlive Technology的最新分析
The Last 12 Months Of Insider Transactions At Medlive Technology
Medlive Technology最近12個月的內幕交易
Over the last year, we can see that the biggest insider sale was by the VP, Deputy Head of Medical Information Science Research Unit & Executive Director, Lijun Tian, for HK$2.1m worth of shares, at about HK$14.13 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is HK$8.06. So it is hard to draw any strong conclusion from it. The only individual insider seller over the last year was Lijun Tian.
過去一年,我們可以看到,最大的內幕出售是董事副總裁兼醫學資訊科學研究部門副主管兼高管田麗君,以每股約14.13港元的價格購買了價值210萬港元的股票。我們通常不喜歡看到內幕銷售,但售價越低,我們就越擔心。令人欣慰的是,此次出售的價格遠遠高於目前8.06港元的股價。因此,很難從中得出任何強有力的結論。去年唯一的個人內幕賣家是田麗君。
Lijun Tian ditched 200.00k shares over the year. The average price per share was CN¥13.60. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
田立軍在過去一年裡拋售了20萬股股票。每股均價為13.60加元。你可以看到過去一年的內幕交易(由公司和個人),如下圖所示。如果你想知道到底是誰賣了,賣了多少錢,什麼時候賣的,只需點擊下面的圖表!
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
對於那些想要找到贏得投資這免費最近有內幕收購的不斷增長的公司名單可能就是合適的選擇。
Insider Ownership Of Medlive Technology
Medlive Technology的內部人所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 1.1% of Medlive Technology shares, worth about HK$62m, according to our data. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
看看一家公司的內部人持股總數,可以幫助你瞭解他們是否與普通股股東很好地結合在一起。通常,內部人持股越高,內部人就越有可能受到激勵,建立長期的公司。根據我們的數據,內部人士持有Medlive Technology 1.1%的股份,價值約6200萬港元。然而,我們確實注意到,內部人士可能通過私人公司或其他公司結構擁有間接利益。總體而言,這種所有權水準並不令人印象深刻,但肯定比什麼都沒有好!
So What Do The Medlive Technology Insider Transactions Indicate?
那麼,Medlive Technology Insider交易表明了什麼?
The fact that there have been no Medlive Technology insider transactions recently certainly doesn't bother us. We don't take much encouragement from the transactions by Medlive Technology insiders. But it's good to see that insiders own shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Medlive Technology. You'd be interested to know, that we found 1 warning sign for Medlive Technology and we suggest you have a look.
最近沒有發生Medlive Technology的內幕交易,這一事實當然不會讓我們感到困擾。我們不會從Medlive Technology內部人士的交易中獲得太多鼓勵。但看到內部人士持有該公司的股份是件好事。除了瞭解正在進行的內幕交易外,識別Medlive Technology面臨的風險也是有益的。你會有興趣知道的,我們發現1個對Medlive科技的警告標誌我們建議你去看看。
But note: Medlive Technology may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:Medlive Technology可能不是最值得買入的股票。所以讓我們來看看這個免費高淨資產收益率和低負債的有趣公司名單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前只處理公開市場交易和私下處置直接權益,而不處理衍生工具交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.